Press Release

Article

RWJBarnabas Health Recognized Among 2023’s “100 Hospitals and Health Systems with Great Oncology Programs" by Becker’s Hospital Review

RWJBarnabas Health, together with Rutgers Cancer Institute of New Jersey, has been named among Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs for 2023.

Steven K. Libutti, MD, FACS

Steven K. Libutti, MD, FACS

RWJBarnabas Health, together with Rutgers Cancer Institute of New Jersey, has been named among Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs for 2023. The list honors heath systems that have earned national recognition for their work in driving forward advanced cancer care and research, as well as cancer centers with internationally known specialists, capacity for clinical trials and exceptional safety ratings. 

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health’s partnership has transformed cancer care delivery for New Jersey residents. Combining the research and treatment capabilities of Rutgers Cancer Institute and the clinical expertise of RWJBarnabas Health, the two entities have ensured that all patients have access to high-quality, state-of-the-art cancer care, close to home.

“This recognition demonstrates the high quality, multidisciplinary cancer care we provide for our patients and families in New Jersey and beyond, which is informed by innovative research, discoveries and clinical trials,” said Steven K. Libutti, MD, FACS, Director of Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services, RWJBarnabas Health. “We will continue to transform and expand oncology services across the state, including the construction of the Jack and Sheryl Morris Cancer Center, the state’s first freestanding cancer hospital.”

As New Jersey’s leading cancer program and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Rutgers Cancer Institute and RWJBarnabas Health are also at the forefront of cancer research, providing patients with access to novel treatments that are not yet available through standard clinical practice. The NCI designation is awarded to an elite group of centers nationwide, illustrating the breadth and depth of excellence in leadership and resources on a national scale.

Related Videos
Malcolm Mattes, MD, associate professor, Section of Radiation Oncology, Rutgers Robert Wood Johnson Medical School; radiation oncologist, Rutgers Cancer Institute of New Jersey
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia